On January 22, 2025, in Washington, President Trump’s nominee for the Department of Health and Human Services, Robert F. Kennedy Jr., disclosed significant financial details ahead of his confirmation hearings. The disclosures reveal RFK Jr.’s investments in gene-editing technology and substantial book advances, raising potential conflict of interest concerns.
- Robert F. Kennedy Jr. nominated for health department.
- Disclosures reveal investments and conflicts of interest.
- Plans to divest from biotech firms.
- Stepping down from law firm roles.
- Endorsed Trump after presidential campaign exit.
- Confirmation hearings not yet scheduled.
The financial disclosures indicate that RFK Jr. plans to divest from biotech firms such as CRISPR Therapeutics AG and Dragonfly Therapeutics. Additionally, he will step down from positions at his law firm and the anti-vaccine nonprofit Children’s Health Defense following his endorsement of Trump after ending his presidential campaign.
Robert F. Kennedy Jr.’s nomination has drawn attention due to his previous presidential campaign and subsequent endorsement of Trump. His financial disclosures provide insight into potential conflicts of interest related to his new role overseeing health policy in the U.S. The details include various investments that could influence decisions within the Department of Health and Human Services.
Key points from the disclosures include:
- Investments in CRISPR Therapeutics AG and Dragonfly Therapeutics.
- Substantial advances owed for multiple book projects.
- Plans to divest stock holdings before taking office.
The decision for RFK Jr. to step down from leadership roles is part of an effort to mitigate any perceived conflicts as he prepares for confirmation hearings that have yet to be scheduled. His background in both law and public health advocacy will likely be scrutinized during this process as stakeholders assess how these factors may impact his effectiveness as Secretary of Health.
The financial disclosures surrounding RFK Jr.’s nomination highlight important considerations regarding potential conflicts of interest as he transitions into a key governmental role focused on health policy. His planned divestitures aim to address these issues ahead of upcoming confirmation hearings.
